Communicate topline data for the 12-month treatment phase of ALTISSIMO trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 Mar 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Communicate topline data for the 12-month treatment phase of ALTISSIMO in March 2021”
What we found
Evidence strength A What the grades mean
Later 10-Q and 10-K filings state that topline data from the 12-month treatment phase of the ALTISSIMO Phase 2b trial were reported in March 2021, before the March 31, 2021 deadline.
-
A Graybug Vision, Inc. 10-Q filed 2021-05-14
“In March 2021, we reported topline data from the treatment phase of our Phase 2b trial of GB-102” ✓ confirmed on the page
-
A Graybug Vision, Inc. 10-K filed 2022-03-11
“reported topline data from the 12-month treatment phase in March 2021 (the Core Study)” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Communicate
- Deliverable
- Topline data for ALTISSIMO 12-month treatment phase
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Graybug Vision, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CALC-025254 · Corrections policy